For many individuals, reducing excess body weight can dramatically improve overall health and quality of life
Prescribers seeking evidence-based guidance on the neuropsychiatric or affective side effect profile of GLP-1 receptor agonists, including semaglutide, should refer to the published regulatory safety communications from the FDA and EMA, the SUSTAIN and STEP trial data, and peer-reviewed pharmacovigilance literature examining anhedonia, mood changes, and related adverse events in this drug class
Banga AK et al
The data for Week 26 were then analyzed with an ANCOVA model containing treatment, sex, and age group as fixed effects and baseline value as covariate
Ive put this all in a supplement called Thyro Balance
(3) patients with glycated hemoglobin (HbA1c) 6.5% (HbA1c 6% for those undergoing drug treatment) and 10.5% in the preliminary examination